Pharmacodynamics of 2-{4-[(1E)-1-(hydroxyimino)-2,3-dihydro-1H-inden-5-yl]- 3-(pyridine-4-yl)-1H-pyrazol-1-yl}ethan-1-ol (GDC-0879), a potent and selective B-Raf kinase inhibitor: Understanding relationships between systemic concentrations, phosphorylated mitogen-activated protein kinase kinase 1 inhibition, and efficacy

Journal of Pharmacology and Experimental Therapeutics

Volumn 329, Issue 1, 2009, Pages 360-367

  Wong, Harvey ^a   Belvin, Marcia ^a   Herter, Sylvia ^a   Hoeflich, Klaus P ^a   Murray, Lesley J ^a   Wong, Leo ^a   Choo, Edna F ^a  

^a GENENTECH INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 [4 (1 HYDROXYIMINO 2,3 DIHYDRO 1H INDEN 5 YL) 3 (PYRIDINE 4 YL) 1H PYRAZOL 1 YL]ETHAN 1 OL; B RAF KINASE; GDC 0879; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; PROTEIN SERINE THREONINE KINASE INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; COLORECTAL CARCINOMA; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG POTENCY; DRUG STRUCTURE; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; FEMALE; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; MELANOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR VOLUME; TUMOR XENOGRAFT;

ALGORITHMS; ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; FEMALE; HUMANS; INDENES; MAP KINASE KINASE 1; MICE; MICE, NUDE; MUTATION; NEOPLASM TRANSPLANTATION; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS B-RAF; PYRAZOLES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 63849122381     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.108.148189     Document Type: Article

References (26)

1. Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248-254.
2. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W, et al. (2002) Mutations of the BRAF gene in human cancer. Nature 417:949-954.
3. de Winter W, DeJongh J, Post T, Ploeger B, Urquhart R, Moules I, Eckland D, and DanhofM (2006) Amechanism-based disease progression model for comparison of long-term effects of pioglitazone, metformin and gliclazide on disease processes underlying type 2 diabetes mellitus. J Pharmacokinet Pharmacodyn 33:313-343.
4. Dunnett C (1955) A multiple comparison procedure for comparing several treatments with a control. J Am Stat Assoc 50:1096-1121.
5. Earp JC, Dubois DC, Molano DS, Pyszczynski NA, Almon RR, and Jusko WJ (2008a) Modeling corticosteroid effects in a rat model of rheumatoid arthritis II: mechanistic pharmacodynamic model for dexamethasone effects in Lewis rats with collagen-induced arthritis. J Pharmacol Exp Ther 326:546-554.
6. Earp JC, Dubois DC, Molano DS, Pyszczynski NA, Keller CE, Almon RR, and Jusko WJ (2008b) Modeling corticosteroid effects in a rat model of rheumatoid arthritis I: mechanistic disease progression model for the time course of collagen-induced arthritis in Lewis rats. J Pharmacol Exp Ther 326:532-545.
7. Friday BB and Adjei AA (2008) Advances in targeting the Ras/Raf/MEK/Erk mito-gen-activated protein kinase cascade with MEK inhibitors for cancer therapy. Clin Cancer Res 14:342-346.
8. Gollob JA, Wilhelm S, Carter C, and Kelley SL (2006) Role ofRaf kinase in cancer: therapeutic potential oftargetingthe Raf/MEK/ERK signal transduction pathway. Semin Oncol 33:392-406.
9. Hansen JD, Grina J, Newhouse B, Welch M, Topalov G, Littman N, Callejo M, Gloor S, Martinson M, Laird E, et al. (2008) Potent and selective pyrazole-based inhibitors of B-Raf kinase. Bioorg Med Chem Lett 18:4692-4695.
10. Huang CY and Ferrell JE Jr (1996) Ultrasensitivity in the mitogen-activated protein kinase cascade. Proc Natl Acad Sci U S A 93:10078-10083.
11. Jang SH, Wientjes MG, Lu D, and Au JL (2003) Drug delivery and transport to solid tumors. Pharm Res 20:1337-1350.
12. Kelland LR (2004) Of mice and men: values and liabilities of the athymic nude mouse model in anticancer drug development. Eur J Cancer 40:827-836.
13. Khazak V, Astsaturov I, Serebriiskii IG, and Golemis EA (2007) Selective Raf inhibition in cancer therapy. Expert Opin Ther Targets 11:1587-1609.
14. N, Batt D, and Warmuth M (2007) B-Raf kinase inhibitors for cancer treatment. Curr Opin Investig Drugs 8:452-456.
15. Madhunapantula SVand Robertson GP (2008) Is B-Rafa good therapeutic target for melanoma and other malignancies? Cancer Res 68:5-8.
16. Mager DE, Wyska E, and Jusko WJ (2003) Diversity of mechanism-based pharma - codynamic models. DrugMetab Dispos 31:510-518.
17. McCubrey JA, Steelman LS, Chappell WH, Abrams SL, Wong EW, Chang F, Leh-mann B, Terrian DM, Milella M, Tafuri A, et al. (2007) Roles ofthe Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim Biophys Acta 1773:1263-1284.
18. Mercer KE and Pritchard CA (2003) Raf proteins and cancer: B-Raf is identified as a mutational target. Biochim Biophys Acta 1653:25-40.
19. Schreck R and Rapp UR (2006) Raf kinases: Oncogenesis and drug discovery. Int J Cancer Sebolt-Leopold JS and Herrera R (2004) Targeting the mitogen-activated protein kinase cascade to treat cancer. Nat Rev Cancer 4:937-947.
20. Tan W, DePrimo SE, Krishnamurthi SS, Rinehart JJ, Nabell LM, Nickens D, Bentivegna S, Wilner KD, et al. (2007) Pharmacokinetic (PK) and pharmacody-namic (PD) results of a phase I study of PD-0325901, a second generation oral MEK inhibitor, in patients with advanced cancer. American Association of Cancer Research-National Institute of Cancer-European Organization for Research and Treatment of Cancer Conference; 2007 October, San Francisco, CA.
21. Tanaka C, O'Reilly T, Kovarik JM, Shand N, Hazell K, Judson I, Raymond E, Zumstein-Mecker S, Stephan C, Boulay A, et al. (2008) Identifying optimal biologic doses of everolimus (RAD001) in patients with cancer based on the modeling of preclinical and clinical pharmacokinetic and pharmacodynamic data. JClin Oncol 26:1596 - 1602.
22. Teicher BA (2006) Tumor models for efficacy determination. Mol Cancer Ther 5:2435-2443.
23. Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, Chen C, Zhang X, Vincent P, McHugh M, et al. (2004) BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 64:7099 - 7109.
24. Yamazaki S, Skaptason J, Romero D, Lee JH, Zou HY, Christensen JG, Koup JR, Smith BJ, and Koudriakova T (2008) Pharmacokinetic-pharmacodynamic model ing of biomarker response and tumor growth inhibition to an orally available cMet kinase inhibitor in human tumor xenograft mouse models. Drug Metab Dispos 36:1267-1274.
25. Yuen ST, Davies H, Chan TL, Ho JW, Bignell GR, CoxC, Stephens P, Edkins S, Tsui WW, Chan AS, et al. (2002) Similarity of the phenotypic patterns associated with BRAF and KRAS mutations in colorectal neoplasia. Cancer Res 62:6451-6455.
26. Zebisch A and Troppmair J (2006) Back to the roots: the remarkable RAF oncogene story. Cell Mol Life Sci 63:1314-1330.